Accelerated Chemotherapy for Small-Cell Lung Cancer
Author Information
Author(s): Sculier J P, Paesmans M, Lecomte J, Van Cutsem O, Lafitte J J, Berghmans T, Koumakis G, Florin M C, Thiriaux J, Michel J, Giner V, Berchier M C, Mommen P, Ninane V, Klastersky J
Primary Institution: Institut Jules Bordet
Hypothesis
Does accelerated chemotherapy improve survival in patients with extensive-disease small-cell lung cancer?
Conclusion
The study found no survival benefit from accelerated chemotherapy using GM-CSF support in patients with extensive-disease small-cell lung cancer.
Supporting Evidence
- 233 eligible patients were randomised.
- Best response rates were 59% for standard chemotherapy, 76% for accelerated chemotherapy with GM-CSF, and 70% for accelerated chemotherapy with antibiotics.
- The response rate was significantly higher in the GM-CSF group compared to the standard group.
Takeaway
The study tested a faster way to give chemotherapy to lung cancer patients, but it didn't help them live longer.
Methodology
Patients were randomized into three groups to receive different chemotherapy regimens, and survival was the primary endpoint.
Limitations
The trial did not demonstrate a survival benefit despite increased response rates in one treatment arm.
Participant Demographics
Patients with extensive-disease small-cell lung cancer.
Statistical Information
P-Value
0.04
Statistical Significance
p=0.04
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website